# Consonance Capital Partners
Consonance Capital Partners (CCP) is a New York-based private equity firm that invests exclusively in United States lower and middle-market healthcare companies, founded by four former JPMorgan Partners colleagues: Mitchell Blutt, MD, Benjamin Edmands, Stephen McKenna, and Nancy-Ann DeParle.[1](https://www.sec.gov/Archives/edgar/data/1824893/000110465920127357/tm2030948-27_424b4.htm) Its current flagship vehicle is Consonance Private Equity II, L.P.; the firm says it has raised over $1.3 billion in equity capital across two funds and is currently investing out of Fund II.[2](https://www.consonancecapitalpartners.com/) The firm remains active as of the record through September 2026, with one fund listed in market by Private Equity International.[3](https://www.privateequityinternational.com/institution-profiles/consonance-capital-partners.html)
| Key fact | Detail |
|---|---|
| Headquarters | New York, United States[3](https://www.privateequityinternational.com/institution-profiles/consonance-capital-partners.html) |
| Platform origin | Consonance Capital platform created in 2005; PE business founding year not independently documented[4](https://www.consonancecapital.com/) |
| Founders | Mitchell Blutt, MD, Benjamin Edmands, Stephen McKenna, Nancy-Ann DeParle, former JPMorgan Partners colleagues[1](https://www.sec.gov/Archives/edgar/data/1824893/000110465920127357/tm2030948-27_424b4.htm) |
| Sector | Healthcare-only private equity, U.S. lower and middle market[5](https://www.9at.com/Adviser/801-77800) |
| Funds | Fund II closed at its $856 million hard cap inclusive of the GP commitment, with the final close on April 8, 2020, per the firm's announcement[6](https://www.businesswire.com/news/home/20200427005529/en/Consonance-Capital-Partners-Closes-Fund-II-at-Hard-Cap-of-856-Million) |
| Discretionary AUM | Approximately $2.24 billion as of December 31, 2023[5](https://www.9at.com/Adviser/801-77800) |
| Status (through Sept 2026) | Active, investing out of Fund II; 1 fund in market per PEI[3](https://www.privateequityinternational.com/institution-profiles/consonance-capital-partners.html) |
## Structure of the Consonance platform
The Consonance Capital platform, created in 2005, has three main arms: the private equity business (Consonance Capital Partners), a public life sciences hedge fund manager (Consonance Capital Management), and, in 2020, a life sciences SPAC sponsor formed by the founders of the hedge fund.[1](https://www.sec.gov/Archives/edgar/data/1824893/000110465920127357/tm2030948-27_424b4.htm) Consonance Capital Management was founded in 2007 by Mitchell Blutt with Benny Soffer, MD, and Kevin Livingston, starting with approximately $50 million of assets under management and growing to over $1 billion as of September 1, 2020, focused on small and mid-cap publicly traded life sciences companies.[1](https://www.sec.gov/Archives/edgar/data/1824893/000110465920127357/tm2030948-27_424b4.htm) That affiliate is now no longer making new equity investments, according to the platform's own site.[4](https://www.consonancecapital.com/)
The private equity vehicles use a layered general-partner structure: Consonance Private Equity GP, LLC, a Delaware limited liability company, serves as the Upper GP for the Lower GP I, Lower GP II, GP Capital Vehicle, and GP Carry Vehicle entities, alongside co-investment vehicles for specific deals.[5](https://www.9at.com/Adviser/801-77800)
## Founders and people
Mitchell Blutt, a physician-investor, was an Executive Partner at JP Morgan Partners from 1992 until 2004, where he founded and led JPMP's healthcare group. He is founder and CEO of Consonance Capital and Co-Managing Partner and Co-Founder of Consonance Capital Partners.[1](https://www.sec.gov/Archives/edgar/data/1824893/000110465920127357/tm2030948-27_424b4.htm) The firm's site says the four founders partnered together for over a decade at JPMorgan Partners and its predecessor and successor entities and have over 90 years of combined private equity experience, primarily in healthcare.[2](https://www.consonancecapitalpartners.com/)
The founders serve as the firm's principal owners and sit on the investment committees; Javier Starkand and Sean Breen joined Blutt, Edmands, McKenna and DeParle on Fund II's investment committee.[5](https://www.9at.com/Adviser/801-77800)
## Investment strategy
CCP targets growth equity, leveraged buyouts, and recapitalization transactions in U.S. middle-market healthcare companies. The revenue bands have widened between funds: $20 to $150 million for Fund I and $25 to $500 million for Fund II, according to the firm's Form ADV.[5](https://www.9at.com/Adviser/801-77800) The firm's own site describes the same $25 million to $500 million revenue target.[2](https://www.consonancecapitalpartners.com/)
## Funds raised
**Fund II.** Consonance Private Equity II, L.P. closed at its hard cap of $856 million, inclusive of the GP commitment, with the final close on April 8, 2020, under three months after the initial close, according to the firm's announcement.[6](https://www.businesswire.com/news/home/20200427005529/en/Consonance-Capital-Partners-Closes-Fund-II-at-Hard-Cap-of-856-Million) The firm said Fund II drew support from existing investors and a select number of new limited partners spanning insurers, endowments, foundations, family offices, asset managers, funds of funds, pension plans, and strategic healthcare providers in the United States and Europe.[6](https://www.businesswire.com/news/home/20200427005529/en/Consonance-Capital-Partners-Closes-Fund-II-at-Hard-Cap-of-856-Million) Monument Group served as global placement agent and Latham & Watkins LLP as legal counsel.[6](https://www.businesswire.com/news/home/20200427005529/en/Consonance-Capital-Partners-Closes-Fund-II-at-Hard-Cap-of-856-Million)
**Totals and AUM.** The firm states it has raised over $1.3 billion in equity capital across two funds.[2](https://www.consonancecapitalpartners.com/) As of December 31, 2023, the adviser Consonance Capital Partners, LP managed approximately $2.24 billion of the Funds' assets on a discretionary basis.[5](https://www.9at.com/Adviser/801-77800)
## Portfolio and exits
Deal-level data in the retrieved record is thin. Directory-sourced, unverified tracking (Mergr) records 17 transactions for the firm, two exits in its last three years, mostly trade sales, and a largest disclosed exit of [Corindus Vascular Robotics](https://www.edgepedia.org/corindus-vascular-robotics) sold for $1.1 billion in 2019.[7](https://mergr.com/investor/consonance-capital-partners/ma) Mergr also records a December 22, 2025 exit of portfolio company BakoDx, an [Alpharetta, Georgia](https://www.edgepedia.org/alpharetta-georgia) specialty laboratory testing provider; this is unverified beyond the aggregator.[7](https://mergr.com/investor/consonance-capital-partners/ma) Fund performance data is not public in the retrieved record.
## Recent developments
The adviser reported approximately $2.24 billion of discretionary AUM at December 31, 2023.[5](https://www.9at.com/Adviser/801-77800) Private Equity International's profile lists the firm with one fund currently in market as of the retrieved 2026 page.[3](https://www.privateequityinternational.com/institution-profiles/consonance-capital-partners.html) The firm's own site still describes it as investing out of Fund II.[2](https://www.consonancecapitalpartners.com/) The December 2025 BakoDx sale, if confirmed, would be its most recent known exit.[7](https://mergr.com/investor/consonance-capital-partners/ma)
## References
1. Consonance-HFW Acquisition Corp. Form 424B4 prospectus, SEC EDGAR. https://www.sec.gov/Archives/edgar/data/1824893/000110465920127357/tm2030948-27_424b4.htm
2. Consonance Capital Partners, Private Equity, Healthcare, New York. https://www.consonancecapitalpartners.com/
3. Consonance Capital Partners, Institution Profile, Private Equity International. https://www.privateequityinternational.com/institution-profiles/consonance-capital-partners.html
4. Consonance Capital, Healthcare Investors. https://www.consonancecapital.com/
5. Consonance Capital Partners, LP, SEC Form ADV summary (Adviser 801-77800). https://www.9at.com/Adviser/801-77800
6. Consonance Capital Partners Closes Fund II at Hard Cap of $856 Million, Business Wire, April 27, 2020. https://www.businesswire.com/news/home/20200427005529/en/Consonance-Capital-Partners-Closes-Fund-II-at-Hard-Cap-of-856-Million
7. Consonance Capital Partners M&A Activity, Mergr (directory data, unverified). https://mergr.com/investor/consonance-capital-partners/ma
---
*Topic: Encyclopedia › Society and history › Economics and business › Finance › Venture capital and private equity › Private equity and buyout firms of the Americas › Buyout and control firms*
*Initially written Sep 17, 2026 · Reviewed: Sep 30, 2026 · Edited: Sep 30, 2026; Oct 11, 2026; Oct 15, 2026; Nov 11, 2026 · Last review: Sep 30, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license